Will Newly Approved Centanafadine Transform ADHD Care?
Physician's Weekly
The article is written in English. The FDA has approved centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), as the first CNS stimulant for treating ADHD in adults and children aged six and older. Clinical trials demonstrated that this once-daily medication produces statistically significant and clinically meaningful improvements in ADHD symptoms starting as early as Week 1.
All articles from 8 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.